ALS Ltd Stock
€12.20
Your prediction
Pros and Cons of ALS Ltd in the next few years
Pros
Cons
Performance of ALS Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| ALS Ltd | - | 0.826% | 0.826% | 29.101% | 36.313% | 63.758% | 110.345% |
| Seek Ltd | 0.000% | 0.000% | -8.163% | -12.338% | -0.735% | -2.878% | -15.625% |
| Downer EDI Ltd | 0.920% | 0.461% | 2.347% | 28.235% | 39.744% | 80.165% | 32.927% |
| Insperity Inc. | 0.000% | -1.961% | 2.041% | -60.784% | -58.621% | -72.727% | -58.042% |
News
North American Niobium and Critical Minerals Corp. Completes Phase 1 Fall Prospecting Program; Carbonatite and Pegmatite Targets Identified Across Québec Properties
- Completion of Fall 2025 Prospecting Program Across Seigneurie, Bardy, Blanchette and Sabot Properties
- Carbonatite Boulders and Pegmatite Zones Identified
- 262
Electromed Posts 17% Gain in Fiscal Q4
Electromed (NYSEMKT:ELMD), a medical device company specializing in airway clearance therapy, reported record financial results for the quarter and fiscal year ended August 26, 2025. The company’s
Clene Posts 70% Revenue Drop in Q2
Clene (NASDAQ:CLNN), a clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases, released its second-quarter 2025 earnings on August 14, 2025. The most important


